ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Hashmi on Immunotherapy in Prostate Cancer

Mehmood Hashmi, MD
Published: Tuesday, Jul 17, 2018



Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses the use of immunotherapy in the treatment of patients with prostate cancer.

As in many other cancers, immunotherapy is another available pillar of treatment, says Hashmi. Prostate cancer is a very immunogenic disease, and neoantigens are produced that can be targeted. Single-agent immunotherapy has induced response rates of approximately 10%. Combination therapies are now being explored in an attempt to further enhance response rates. Some of these strategies include dual immunotherapeutic approaches as well as immunotherapy in combination with androgen suppression, explains Hashmi.

In addition to developing synergistic combinations, Hashmi notes that physicians have to identify specific genes through genomic-based testing to further personalize treatments. Even with these advances, immunotherapy will be restricted to certain subsets of patients, states Hashmi.


Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses the use of immunotherapy in the treatment of patients with prostate cancer.

As in many other cancers, immunotherapy is another available pillar of treatment, says Hashmi. Prostate cancer is a very immunogenic disease, and neoantigens are produced that can be targeted. Single-agent immunotherapy has induced response rates of approximately 10%. Combination therapies are now being explored in an attempt to further enhance response rates. Some of these strategies include dual immunotherapeutic approaches as well as immunotherapy in combination with androgen suppression, explains Hashmi.

In addition to developing synergistic combinations, Hashmi notes that physicians have to identify specific genes through genomic-based testing to further personalize treatments. Even with these advances, immunotherapy will be restricted to certain subsets of patients, states Hashmi.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x